Identifying patients who benefit most from treatments for Alzheimer's disease and related dementias.
Official title: Statistical methods to characterize patients who highly benefit across multifaceted clinical outcomes, from treatments in Alzheimers Disease and Related Dementias (ADRD)
Funded at Johns Hopkins University · NIH-11078273 · Data updated 2026-11-12
This study is looking to find out which patients with Alzheimer's and related dementias are most likely to benefit from certain treatments, so we can help them get the best care possible while keeping any risks low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | May 1, 2024 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $396,172 |
| NIH project number | 5R01AG083423-02 |
| Project ID | NIH-11078273 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related dementias who are seeking treatment options.
✕Less likely to help
Patients with early-stage cognitive impairment or those not diagnosed with Alzheimer's disease or related dementias may not benefit from this research.
What this research studies
This research aims to develop statistical methods to identify patients who will experience significant benefits from treatments for Alzheimer's disease and related dementias across multiple clinical outcomes. By analyzing various patient characteristics, the study seeks to predict which individuals are likely to gain the most from specific therapies while minimizing potential harms. The approach involves constructing outcome predictions based on a wide range of patient data and synthesizing these predictions to create a profile of high-benefit patients. This innovative methodology addresses the current gap in accurately characterizing patients who can benefit from treatment.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment options for patients with Alzheimer's disease, improving their quality of life.
How similar studies have gone: Previous research has shown promise in using statistical methods to improve patient outcomes in similar contexts, indicating a potential for success in this novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Frangakis, Constantine E — Johns Hopkins University
- Study coordinator: Frangakis, Constantine E
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Cognitive SuperAging: Exploring why some octogenarians stay sharp in memory
This NIH grant studies why a small group of people aged 80+ keep memory skills as good as much younger people, hoping to understand how to protect memory as we age.
-
CLU's role in Alzheimer's disease pathogenesis
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.